Phase I Pharmacokinetic Study of Nivolumab in Korean Patients with Advanced Solid Tumors

LESSONS LEARNED. This pharmacokinetic study of nivolumab showed that there is little ethnic difference in the handling of nivolumab. Nivolumab was well tolerated in Korean patients. BACKGROUND. This phase I study of nivolumab, an anti‐programmed cell death‐1 (anti‐PD‐1) monoclonal antibody, investig...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Keun‐Wook, Lee, Dae Ho, Kang, Jin Hyoung, Park, Joon Oh, Kim, Se Hyun, Hong, Yong Sang, Kim, Seung Tae, Oh, Do‐Youn, Bang, Yung‐Jue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2017
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813749/
https://www.ncbi.nlm.nih.gov/pubmed/29158363
http://dx.doi.org/10.1634/theoncologist.2017-0528

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813749/
https://www.ncbi.nlm.nih.gov/pubmed/29158363
http://dx.doi.org/10.1634/theoncologist.2017-0528

Ejemplares similares